In this study, we explored the use of pre-clinical cell line drug response data alongside computational modeling to determine the optimal dosages of pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors for melanoma treatment. This evidence concerns the gene RAF1 and melanoma.